Performance Testing in Clinical Conditions

GMLP Principle 8. Design clinical performance studies that produce defensible, clinically meaningful evidence: across subgroups, in realistic conditions.

Overview

Clinical performance studies often disappoint because the design optimized for feasibility instead of evidence quality. Independent test sets get conflated with training sets through sloppy split design. Subgroup performance is treated as a footnote. Endpoints are chosen for convenience instead of clinical meaningfulness.

We design performance testing as the evidence backbone of your regulatory submission and commercial story: independent, subgroup-aware, clinically meaningful.

Our Process

  1. 1

    Endpoint selection

    Clinically meaningful primary and secondary endpoints.

  2. 2

    Test set construction

    Independent across all dependency dimensions.

  3. 3

    Subgroup planning

    Pre-specified subgroup analyses with power.

  4. 4

    Execution oversight

    Study conduct, monitoring, deviation management.

  5. 5

    Reporting

    Submission-ready performance report.

Frequently Asked Questions

Can we use retrospective test sets?

Often yes, with care. Prospective is stronger but slower.

Subgroup pre-specification matters?

Critical. Post-hoc subgroup analyses are heavily discounted.

What about multi-reader studies?

Common for image-interpretation devices; designed per FDA expectations.

Standards alignment?

TRIPOD-AI, CONSORT-AI, STARD-AI, FDA performance testing guidance.

Build the evidence backbone.

Tell us your endpoint hypothesis and target submission. We will return a study design within five weeks.

Start a Conversation